1. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. (February 2022) Authors: Danese, Silvio; Colombel, Jean-Frederic; Lukas, Milan; Gisbert, Javier P; D'Haens, Geert; Hayee, Bu'hussain; Panaccione, Remo; Kim, Hyun-Soo; Reinisch, Walter; Tyrrell, Helen; Oh, Young S; Tole, Swati; Chai, Akiko; Chamberlain-James, Kirsten; Tang, Meina Tao; Schreiber, Stefan; Aboo, Nazimuddin; ... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 2(2022) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Successful use of TNFα blockade in a severe case of idiopathic non-granulomatous ulcerative jejunoileitis associated with thrombotic thrombocytopenic purpura. Issue 1 (8th February 2019) Authors: Braun, Fabian; Suarez, Victor; Dinter, Johanna; Haneder, Stefan; Quaas, Alexander; Benzing, Thomas; Nierhoff, Dirk; Müller, Roman-Ulrich Journal: BMJ open gastroenterology Issue: Volume 6:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗